Tim J. Wigle

5.6k citations

48 papers · 4.8k · 2 hit papers · h-index 28

Impact in

Molecular Biology top 1%
- Epigenetics and DNA Methylation
- Cancer-related gene regulation
- Chromatin Remodeling and Cancer
- Protein Degradation and Inhibitors
Oncology top 10%
- PARP inhibition in cancer therapy

Papers in

Molecular Biology 25
- Epigenetics and DNA Methylation 12
- Cancer-related gene regulation 8
- Protein Degradation and Inhibitors 2
- Enzyme function and inhibition 1
Oncology 3
- PARP inhibition in cancer therapy 3

Co-authors: Robert A. Copeland (15 shared papers)Kevin W. Kuntz (16 shared papers)Mikel P. Moyer (11 shared papers)Margaret Porter Scott (11 shared papers)Sarah K. Knutson (9 shared papers)Heike Keilhack (10 shared papers)Victoria M. Richon (7 shared papers)Richard Chesworth (9 shared papers)
Journals: Journal of Medicinal Chemistry (4 papers)SLAS DISCOVERY (4 papers)Blood (3 papers)ACS Medicinal Chemistry Letters (3 papers)PLoS ONE (3 papers)
Partner nations: United States Canada Japan

In The Last Decade

Tim J. Wigle

45 papers receiving 4.5k citations

Tim J. Wigle's Hit Papers

align trajectories log scale

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 2013 · 661 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2013 Proceedings of the National Academy of Sciences
2012 Nature Chemical Biology

Peers

Countries citing papers authored by Tim J. Wigle

Since Specialization

Citations

This map shows the geographic impact of Tim J. Wigle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim J. Wigle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim J. Wigle more than expected).

Fields of papers citing papers by Tim J. Wigle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim J. Wigle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim J. Wigle. The network helps show where Tim J. Wigle may publish in the future.

Co-authors

The 25 scholars most cited alongside Tim J. Wigle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tim J. Wigle Line = papers co-authored together Tim J. Wigle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nature Chemical Biology ·Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, Christopher J. Sneeringer, Christina J. Allain, Christine R. Klaus, Joelle Sacks Suarez, Alejandra Raimondi Hit paper breakdown →	2012	663
2	Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proceedings of the National Academy of Sciences ·Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth Hit paper breakdown →	2013	661
3	A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Nature Chemical Biology ·Elayne Chan-Penebre, Kristy G. Kuplast-Barr, Christina R. Majer, P. Ann Boriack‐Sjodin, Tim J. Wigle, L. Danielle Johnston, Nathalie Rioux-Leclerq, Michael J. Munchhof	2015	467
4	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells Nature Chemical Biology ·Masoud Vedadi, Dalia Baršytė-Lovejoy, Feng Liu, Sylvie Rival‐Gervier, Abdellah Allali‐Hassani, Viviane Labrie, Tim J. Wigle, Peter A. DiMaggio	2011	463
5	Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma Molecular Cancer Therapeutics ·Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan‐Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi	2014	460
6	Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines. Journal of Medicinal Chemistry ·Feng Liu, Xin Chen, Abdellah Allali‐Hassani, Amy M. Quinn, Tim J. Wigle, Gregory A. Wasney, Aiping Dong, Guillermo A. Senisterra	2010	187
7	The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat Journal of Medicinal Chemistry ·Kevin W. Kuntz, Heike Keilhack, Roy M. Pollock, Sarah K. Knutson, Margaret Porter-Scott, Victoria M. Richon, Chris Sneeringer, Tim J. Wigle	2016	145
8	PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity Cancer Cell ·Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Ziying Lu, Jennifer R. Molina	2021	129
9	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni, Lei Jin, Scott R. Daigle, Christina R. Majer, Carly A. Therkelsen, Tim J. Wigle, Kevin W. Kuntz, Richard Chesworth	2012	128
10	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients FEBS Letters ·Christina R. Majer, Lei Jin, Margaret Porter Scott, Sarah K. Knutson, Kevin W. Kuntz, Heike Keilhack, Jesse Joshua Smith, Mikel P. Moyer	2012	126
11	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity ACS Medicinal Chemistry Letters ·Kevin W. Kuntz, Sarah K. Knutson, Natalie M. Warholic, Heike Keilhack, Tim J. Wigle, Alejandra Raimondi, Christine R. Klaus, Nathalie Rioux-Leclerq	2015	112
12	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound ACS Medicinal Chemistry Letters ·Lorna H. Mitchell, Allison E. Drew, Scott A. Ribich, Nathalie Rioux-Leclerq, Kerren K. Swinger, Suzanne L. Jacques, Trupti Lingaraj, P. Ann Boriack‐Sjodin	2015	110
13	Small-Molecule Ligands of Methyl-Lysine Binding Proteins Journal of Medicinal Chemistry ·J. Martin Herold, Tim J. Wigle, Jacqueline L. Norris, Robert Lam, Victoria Korneeva Korboukh, Cen Gao, Lindsey A. Ingerman, Dmitri Kireev	2011	103
14	Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins SLAS DISCOVERY ·Tim J. Wigle, J. Martin Herold, Guillermo A. Senisterra, Masoud Vedadi, Dmitri Kireev, C.H. Arrowsmith, Stephen V. Frye, William P. Janzen	2009	77
15	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor ACS Medicinal Chemistry Letters ·Lorna H. Mitchell, P. Ann Boriack‐Sjodin, Sherri A. Smith, Michael J. Thomenius, Nathalie Rioux-Leclerq, Michael J. Munchhof, James E. J. Mills, Christine R. Klaus	2015	73
16	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Letters ·Tim J. Wigle, Sarah K. Knutson, Lei Jin, Kevin W. Kuntz, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland, Margaret Porter Scott	2011	72
17	Novel Inhibitors of E. coli RecA ATPase Activity PubMed ·Jonathan Zachary Sexton, Tim J. Wigle, Qingping He, Ginger R. Smith, Scott F. Singleton, Alfred L. Williams, Li-An Yeh +1 other	2010	62
18	Directed molecular screening for RecA ATPase inhibitors Bioorganic & Medicinal Chemistry Letters ·Tim J. Wigle, Scott F. Singleton	2007	61
19	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS ONE ·Sarah K. Knutson, Natalie M. Warholic, L. Danielle Johnston, Christine R. Klaus, Tim J. Wigle, Dorothy Iwanowicz, Bruce A. Littlefield, Margaret Porter-Scott	2014	60
20	Inhibitors of RecA Activity Discovered by High-Throughput Screening: Cell-Permeable Small Molecules Attenuate the SOS Response in Escherichia coli SLAS DISCOVERY ·Tim J. Wigle, Jonathan Zachary Sexton, Anna V. Gromova, Mallinath B. Hadimani, Ginger R. Smith, Li-An Yeh, Scott F. Singleton +1 other	2009	56

About Tim J. Wigle

Tim J. Wigle is a scholar working on Molecular Biology, Oncology, Immunology, Genetics and Spectroscopy, having authored 48 papers that have together received 4.8k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (12 papers), Cancer-related gene regulation (8 papers), PARP inhibition in cancer therapy (3 papers), Protein Degradation and Inhibitors (2 papers), Bacterial Genetics and Biotechnology (2 papers), Enzyme function and inhibition (1 paper), interferon and immune responses (1 paper) and Lymphoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Molecular Biology (2.4k citations), Oncology (214 citations), Computational Theory and Mathematics (138 citations), Pathology and Forensic Medicine (132 citations) and Hematology (105 citations). Tim J. Wigle has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Robert A. Copeland, Kevin W. Kuntz, Mikel P. Moyer, Margaret Porter Scott, Sarah K. Knutson, Heike Keilhack, Victoria M. Richon, Richard Chesworth, Roy M. Pollock and Natalie M. Warholic. Their work appears in journals such as Journal of Medicinal Chemistry, SLAS DISCOVERY, Blood, ACS Medicinal Chemistry Letters and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tim J. Wigle

Impact in

Papers in i

In The Last Decade

Tim J. Wigle

Tim J. Wigle's Hit Papers

Peers

Countries citing papers authored by Tim J. Wigle

Fields of papers citing papers by Tim J. Wigle

All Works

About Tim J. Wigle

Explore authors with similar magnitude of impact

Papers in